33 related articles for article (PubMed ID: 19854051)
1. Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors.
Mohamady S; Galal M; Eldehna WM; Gutierrez DC; Ibrahim HS; Elmazar MM; Ali HI
ACS Omega; 2020 Aug; 5(30):18872-18886. PubMed ID: 32775889
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Novel Series of Potent TrkA Receptor Tyrosine Kinase Inhibitors.
Raeppel SL; Gaudette F; Nguyen H; Beaulieu N; Wang J; Maroun C; Besterman JM; Vaisburg A
Int J Med Chem; 2012; 2012():412614. PubMed ID: 25954527
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity.
Zhan Z; Ai J; Liu Q; Ji Y; Chen T; Xu Y; Geng M; Duan W
ACS Med Chem Lett; 2014 Jun; 5(6):673-8. PubMed ID: 24944742
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel c-Met inhibitors bearing a 3-carboxyl piperidin-2-one scaffold.
Zhang W; Ai J; Shi D; Peng X; Ji Y; Liu J; Geng M; Li Y
Molecules; 2014 Feb; 19(2):2655-73. PubMed ID: 24566328
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor receptor-2 in breast cancer.
Guo S; Colbert LS; Fuller M; Zhang Y; Gonzalez-Perez RR
Biochim Biophys Acta; 2010 Aug; 1806(1):108-21. PubMed ID: 20462514
[TBL] [Abstract][Full Text] [Related]
6. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.
Dussault I; Bellon SF
Anticancer Agents Med Chem; 2009 Feb; 9(2):221-9. PubMed ID: 19199866
[TBL] [Abstract][Full Text] [Related]
7. N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Raeppel S; Claridge S; Saavedra O; Gaudette F; Zhan L; Mannion M; Zhou N; Raeppel F; Granger MC; Isakovic L; Déziel R; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman J; Vaisburg A
Bioorg Med Chem Lett; 2009 Mar; 19(5):1323-8. PubMed ID: 19211249
[TBL] [Abstract][Full Text] [Related]
8. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
[TBL] [Abstract][Full Text] [Related]
11. N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Saavedra O; Claridge S; Zhan L; Raeppel F; Granger MC; Raeppel S; Mannion M; Gaudette F; Zhou N; Isakovic L; Bernstein N; Déziel R; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Wang J; Macleod AR; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2009 Dec; 19(24):6836-9. PubMed ID: 19896842
[TBL] [Abstract][Full Text] [Related]
12. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present).
Lv PC; Wang ZC; Zhu HL
Curr Med Chem; 2017; 24(1):57-64. PubMed ID: 27804876
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
